跳至主要内容
临床试验/NCT07562464
NCT07562464尚未招募3 期

Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations

Capital Medical University0 个研究点目标入组 222 人开始时间: 2026年5月20日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
222
主要终点
Percentage change in hemoglobin and hematocrit from baseline.

研究概览

简要总结

This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The participants are adult patients with high-altitude polycythemia who have been long-term residents (for >6 months) in regions at an altitude of ≥2500 meters. Participants are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 90-day RIC intervention, as an add-on to conventional medication, in managing high-altitude polycythemia.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥18 years, of either sex; Continuous residence in a high-altitude region (≥2500 meters) for more than 6 months, with no plan for long-term departure from the plateau during the study period; Meeting the diagnostic criteria for high-altitude polycythemia; Willing to provide written informed consent.

排除标准

  • Other hematologic diseases, such as anemia or abnormal leukocytosis; Severe dysfunction of vital organs (e.g., heart, liver, kidney, lungs); Active malignancy, uncontrolled hyperthyroidism, active autoimmune disease, or poorly controlled diabetes mellitus; Pregnancy, planned pregnancy, or lactation for female participants; Contraindications to RIC (e.g., severe peripheral arterial disease, venous thrombosis, or soft tissue injury in the upper limbs); Any other condition deemed by the investigator to be unsuitable for participation in the study.

研究组 & 干预措施

RIC group

Experimental

干预措施: RIC (Device)

Control group

No Intervention

结局指标

主要结局

Percentage change in hemoglobin and hematocrit from baseline.

时间窗: 90 days

次要结局

未报告次要终点

研究者

发起方
Capital Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ji Xunming,MD,PhD

PhD

Capital Medical University

相似试验